SEC Comment Letter for Ocugen, Inc. (OCGN) (CIK 0001372299) (OCGN) — Apr 25, 2024
Ocugen, Inc. (OCGN) (CIK 0001372299)
Date: April 25, 2024 · CIK: 0001372299 · Accession: 0000000000-24-004607
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278774
Letter
United States securities and exchange commission logo April 25, 2024 Shankar Musunuri Chief Executive Officer Ocugen, Inc. 11 Great Valley Parkway Malvern, PA 19355 Re:Ocugen, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No. 333-278774 Dear Shankar Musunuri: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Porter
Show Raw Text
United States securities and exchange commission logo
April 25, 2024
Shankar Musunuri
Chief Executive Officer
Ocugen, Inc.
11 Great Valley Parkway
Malvern, PA 19355
Re:Ocugen, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No. 333-278774
Dear Shankar Musunuri:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jennifer Porter